ArticleHeadache
The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies.
Article in Headache. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.The journal of headache and pain · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalcitonin gene-related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety, and combination strategies of gepants.
methodsA scoping review was conducted following PRISMA-ScR recommendations. A comprehensive search of PubMed/MEDLINE and Scopus was performed from database inception to July 2025, with an additional search in January 2026 for real-world studies. Data were extracted and summarized narratively without quantitative synthesis.
resultsSecond- and third-generation gepants, including ubrogepant, rimegepant, atogepant, and zavegepant, overcome the hepatotoxicity and bioavailability limitations of earlier compounds. Pharmacokinetic properties determine their suitability for both acute and preventive use, and their lack of vasoconstrictive activity makes them suitable for patients with cardiovascular comorbidities. Most are metabolized by cytochrome 3A4 and are substrates for efflux transporters, necessitating awareness of drug-drug interactions, although no clinically significant interactions with common migraine preventive medications have been reported. Preclinical and preliminary clinical evidence indicates a low likelihood of gepants inducing medication-overuse headache. Combination therapy with other migraine treatments is mechanistically plausible and supported by early pharmacokinetic and safety data, though robust clinical trial evidence remains limited.
conclusionGepants represent an effective and well-tolerated class of CGRP-targeted therapies with flexible use in acute and preventive migraine management. Their pharmacological properties support individualized treatment strategies and potential combination approaches; however, long-term safety, optimal positioning, and the efficacy of combination regimens require further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.